Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been assigned a consensus rating of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.83.

Several brokerages have commented on AQST. Raymond James began coverage on shares of Aquestive Therapeutics in a research report on Thursday, March 28th. They set an "outperform" rating and a $7.00 price target on the stock. JMP Securities reissued a "market outperform" rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. SVB Leerink assumed coverage on shares of Aquestive Therapeutics in a research note on Friday, May 10th. They set an "outperform" rating and a $8.00 price objective on the stock. Leerink Partnrs upgraded shares of Aquestive Therapeutics to a "strong-buy" rating in a research note on Friday, May 10th. Finally, Piper Sandler assumed coverage on shares of Aquestive Therapeutics in a research note on Thursday, April 11th. They set an "overweight" rating and a $10.00 price objective on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC grew its stake in Aquestive Therapeutics by 314.5% in the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company's stock valued at $7,344,000 after buying an additional 3,642,000 shares during the last quarter. Vanguard Group Inc. grew its stake in Aquestive Therapeutics by 71.7% in the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company's stock valued at $13,813,000 after buying an additional 1,353,518 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in Aquestive Therapeutics in the 4th quarter valued at about $1,709,000. Janney Montgomery Scott LLC acquired a new position in Aquestive Therapeutics in the 1st quarter valued at about $1,456,000. Finally, Legato Capital Management LLC acquired a new position in Aquestive Therapeutics in the 4th quarter valued at about $688,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Stock Up 0.4 %

AQST traded up $0.01 during trading on Friday, hitting $2.60. The company had a trading volume of 12,672,298 shares, compared to its average volume of 1,326,772. The firm's 50-day moving average price is $3.09 and its 200 day moving average price is $3.19. Aquestive Therapeutics has a one year low of $1.25 and a one year high of $6.23. The company has a market capitalization of $236.70 million, a PE ratio of -6.19 and a beta of 2.81.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The business had revenue of $12.05 million for the quarter, compared to analysts' expectations of $12.22 million. During the same quarter in the previous year, the business earned $0.11 earnings per share. Sell-side analysts forecast that Aquestive Therapeutics will post -0.49 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.